StylesCourtArb

[StylesCourtArb @ArbCourt]

@Water46333865 @doepke_michel Check the endoscopic remission data.

[StylesCourtArb @ArbCourt]

@seedy19tron One of the many interested, but not verified.

[StylesCourtArb @ArbCourt]

@Taintslapp12283 Nobody has any. Cursed stock.

[StylesCourtArb @ArbCourt]

@smithy05261244 >Image 7
Now that explains the shit show.

[StylesCourtArb @ArbCourt]

@JackMan724444 @specwiz Colostomy eventually happens in about 50% of Crohn's patients of memory serves.

[StylesCourtArb @ArbCourt]

@Mind_Da_GAAP If top executives moved, it's to close the deal (or start talks, but it's too late for that) and closing happens at the HQs, followed by a nice PR. It doesn't happen on the CEO's porch.

[StylesCourtArb @ArbCourt]

@puppyeh1 Both sides of the argument contain some truth.
Not all change is progress and the Cantillon effect and its destructive consequences are real.
Moreover two fundamentally opposed forces are at work in the economy - the market and the state - and their effects overlap and diverge.

[StylesCourtArb @ArbCourt]

@Ssunten_ Excellent work. Any input on $OTLK? Seems higher risk, considering the contents of its CRL and the recent FDA drama, but potentially higher reward too and is flying under the radar, maybe on account of its small mktcap and treatment alternatives already available in wet ADM.

[StylesCourtArb @ArbCourt]

@Ssunten_ Thanks for clarifying.

[StylesCourtArb @ArbCourt]

@N1neR1seClub Approval seems extremely likely. Any idea about the potential upside given all the warrants outstanding?

[StylesCourtArb @ArbCourt]

@ChudCap Where's the "not my problem" option?

[StylesCourtArb @ArbCourt]

@FibSixOne8 To be honest $MMET.V and $GHRT.V were/are much worse.
I don't see $SRAN.CN's valuation as outrageous. Am I a buyer here? No, but I am keeping an eye on it in case they hit. Good team and promising ground.

[StylesCourtArb @ArbCourt]

@VukasinPekovic @Pete__Panda I agree that GHRT looks better, but I wouldn't be a buyer here at >CAD 100m mkt cap, still room to fall.
I am watching SRAN with interest, but I want to see hits before buying. Hard to justify when you can still buy RAMP at CAD 70m mkt cap with cash on hand and 2nd assays pending

[StylesCourtArb @ArbCourt]

@VukasinPekovic @Pete__Panda GHRT also suffered a re-rate following first drilling results. Will SRAN be next? So far it doesn't look overhyped like the first two.

[StylesCourtArb @ArbCourt]

@virologyanon @akarlin Nothing of significance will happen in the field until immunosenescence and specifically thymic involution are properly recognized as major drivers of ageing, which in turn implies taking a look at microbial load and chronic subclinical infections by presumed """commensals""".

[StylesCourtArb @ArbCourt]

@gringo_in_arg No, the signal is invalid as there's no display of emotion on the cover, cf. Ed Seykota.

[StylesCourtArb @ArbCourt]

@CapitalValor Worthless signal: no display of emotion, see Ed Seykota.

[StylesCourtArb @ArbCourt]

@marketplunger1 No display of emotion on the cover: invalid signal - cf. Ed Seykota.